BUZZ-Aralez Pharmaceuticals Inc: Hits over 2-1/2-year low
** Drug developer's U.S.-listed shares fall 18 pct to $4.76, lowest since May 2013
** Reports Q4 revenue of $6 mln vs $9.9 mln year earlier primarily due to increased costs associated with upcoming launch of its new drug Yosprala
** Net loss was 40 cents per share, compared with a profit of 21 cents per share year earlier
** Up to Monday's close, stock had fallen 15 pct this year
© Thomson Reuters 2017 All rights reserved.